UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: ...
Cibus and Calyxt, which have been pioneering companies in the space of gene edited crops, will merge. “Gene editing is the analog to digital moment for agriculture,” says Rory Riggs ...
The additional shares were made available on September 20, 2024, following the notification from the underwriters to Cibus Inc. Cibus Inc., previously known as Calyxt (NASDAQ:CLXT) Inc., is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback